

This listing of claims will replace all prior versions of claims in the application:

**Listing of Claims:** Please amend the claims as follows:

**We claim:**

**Claim 1. (Currently Amended)** A crystal of an anti-epidermal growth factor receptor (anti-EGFR) antibody which ~~or a variant thereof comprising at least one of~~  
~~(a) conserved substitution in the antibody amino acid sequence;~~  
~~(b) glycosylation of one or more amino acid residues;~~  
~~(c) deglycosylation of one or more amino acid residues; or~~  
~~(d) PEGylation of one or more amino acid residues;~~  
wherein said antibody ~~or said variant~~ forms a biologically active antibody protein when dissolved or suspended in an aqueous medium, said crystal being obtained by a process comprising  
precipitating an aqueous solution or suspension of said anti-EGFR antibody ~~or a variant thereof~~ by means of a precipitation reagent,  
wherein said anti-EGFR antibody is a chimeric monoclonal antibody c225 (cetuximab) ~~or a humanized monoclonal antibody h425.~~

**Claim 2. (Previously Presented)** The crystal according to Claim 1, wherein the precipitation reagent comprises a salt, a polymer, an organic solvent, or a combination thereof.

**Claim 3. (Previously Presented)** The crystal according to Claim 2, wherein the precipitation reagent comprises ammonium sulfate, sodium acetate, sodium citrate, potassium phosphate, PEG and/or ethanol.

**Claim 4. (Canceled)**

**Claim 5. (Canceled)**

**Claim 6. (Canceled)**

**Claim 7. (Canceled)**

**Claim 8. (Cancelled)**

**Claim 9. (Currently Amended)** A process for the preparation of a crystal of an anti-EGFR antibody which ~~or a variant thereof comprising at least one of~~  
~~(a) conserved substitution in the antibody amino acid sequence;~~  
~~(b) glycosylation of one or more amino acid residues;~~  
~~(c) deglycosylation of one or more amino acid residues; or~~  
~~(d) PEGylation of one or more amino acid residues;~~  
wherein ~~said antibody or said variant~~ forms a biologically active antibody protein when dissolved or suspended in an aqueous medium, said process comprising  
precipitating an aqueous solution or suspension of said anti-EGFR antibody ~~or said variant thereof~~ by means of a precipitation reagent, and  
separating the precipitation product,  
wherein said anti-EGFR antibody is monoclonal antibody c225 (cetuximab).

**Claim 10. (Previously Presented)** A process according to Claim 9, wherein the precipitation reagent comprises ammonium sulfate, PEG and/or ethanol.

**Claim 11. (Previously Presented)** A process according to Claim 9, which is carried out in batch format.

**Claim 12. (Previously Presented)** A storage-stable medicament which comprises a crystal of claim 1 together with a stabilizing agent.

**Claim 13. (Previously Presented)** A pharmaceutical preparation which comprises a pharmaceutically acceptable carrier and the crystal according to Claim 1, wherein the anti-EGFR antibody concentration is 50 – 150 mg/ml and said crystal is in crystalline, soluble, or suspended form.

**Claim 14. (Cancelled)**

**Claim 15. (Cancelled)**

**Claim 16. (Cancelled)**

**Claim 17. (Withdrawn)** A method for the treatment and/or prophylaxis of a tumor or a tumor metastasis in a subject in need thereof, comprising administering to said subject a crystal of claim 1.

**Claim 18. (Withdrawn)** A method according to Claim 17, wherein the tumor is brain tumor, tumor of the urogenital tract, tumor of the lymphatic system, stomach tumor, laryngeal tumor, monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.

**Claim 19. (Cancelled)**

**Claim 20. (Cancelled)**

**Claim 21. (Cancelled)**

**Claim 22. (Previously Presented)** The crystal according to Claim 1, which has a size of 50–200  $\mu\text{m}$ .